ESR2 and prostate cancer: Although substantial in vitro analyses have revealed the direct binding to and activation of mutant ARs by BPA, it is also well documented that BPA can activate ERα and ERβ, which are expressed in several prostate cancer cell lines [e.g., LNCaP (human prostatic adenocarcinoma cell line)].